Intellia fine tunes its CRISPR/Cas9 tech ahead of human studies – Endpoints News
Endpoints News |
Intellia fine tunes its CRISPR/Cas9 tech ahead of human studies
Endpoints News One of the handful of gene therapy startups has been fine tuning its CRISPR/Cas9 tech in the lead up to taking it into humans. Building on preclinical work published last summer, investigators at Cambridge, MA-based Intellia $NTLA say they've … |
